Compositions and methods for reducing rna levels
AssigneeThe Regents of the University of California
InventorsLiana Lareau, Fyodor Urnov, Ma. Carmelle Catamura
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for reducing the level of an RNA transcript from a target nucleic acid. The present disclosure provides methods of treating a disease that results from or is caused by a toxic gain-of-function protein. The present disclosure provides systems and compositions for carrying out a method of the present disclosure.
Claims29
A method of reducing the level of an RNA transcript from a target nucleic acid, the method comprising modifying the nucleotide sequence of the target nucleic acid such that a spliced mRNA product of the modified target nucleic acid comprises a stop codon that is not present in a spliced mRNA transcript of the unmodified target nucleic acid and wherein, as a result of the stop codon, the spliced mRNA product undergoes nonsense-mediated mRNA decay, thereby reducing the level of the RNA transcript.
4-5. (canceled)
9-10. (canceled)
13-15. (canceled)
(canceled)
A method for treating a disease caused by a toxic gain-of-function polypeptide in an individual, the method comprising reducing the level of an RNA transcript from a target nucleic acid encoding the toxic gain-of-function polypeptide, comprising modifying the nucleotide sequence of the target nucleic acid such that a spliced mRNA product of the modified target nucleic acid comprises an exon that comprises a stop codon not present in a spliced mRNA product of the unmodified target nucleic acid, wherein the spliced mRNA product undergoes nonsense-mediated mRNA decay, thereby reducing the level of the RNA transcript and treating the disease.
25-26. (canceled)
A system for reducing the level of an RNA transcript from a target nucleic acid in a eukaryotic cell, the system comprising:
- a) a CRISPR-Cas effector polypeptide, or a nucleic acid encoding a CRISPR-Cas effector polypeptide, or a CRISPR-Cas effector fusion polypeptide, or a nucleic acid encoding a CRISPR-Cas effector fusion polypeptide, wherein the CRISPR-Cas effector fusion polypeptide comprises:
- i) the CRISPR-Cas effector polypeptide;
- and ii) one or more heterologous fusion partners;
- b) a guide RNA comprising i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target nucleic acid;
- and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide;
- and
- c) a donor nucleic acid comprising a poison exon insertion nucleotide sequence that provides for insertion of a poison exon into the target nucleic acid, wherein the poison exon insertion nucleotide sequence has a length of from about 21 nucleotides to about 150 nucleotides and comprises, from 5′ to 3′:
- i) a nucleotide sequence of from about 5 nucleotides to about 15 nucleotides in length and having a first consensus splice motif;
- ii) a nucleotide sequence of from about 11 nucleotides to about 15 nucleotides in length and comprising a stop codon in each reading frame;
- and
- iii) a nucleotide sequence of from about 5 nucleotides to about 15 nucleotides in length and having a second consensus splice motif.
28-29. (canceled)
31-32. (canceled)
A composition comprising:
- a) a CRISPR-Cas effector polypeptide, or a nucleic acid encoding a CRISPR-Cas effector polypeptide, or a CRISPR-Cas effector fusion polypeptide, or a nucleic acid encoding a CRISPR-Cas effector fusion polypeptide, wherein the CRISPR-Cas effector fusion polypeptide comprises:
- i) the CRISPR-Cas effector polypeptide;
- and ii) one or more heterologous fusion partners;
- b) a guide RNA comprising i) a targeting region that comprises a nucleotide sequence that binds to a target sequence in the target nucleic acid;
- and ii) a protein-binding region that binds to the CRISPR-Cas effector polypeptide;
- and
- c) a donor nucleic acid comprising a poison exon insertion nucleotide sequence that provides for insertion of a poison exon into the target nucleic acid, wherein the poison exon insertion nucleotide sequence has a length of from about 21 nucleotides to about 150 nucleotides and comprises, from 5′ to 3′:
- i) a nucleotide sequence of from about 5 nucleotides to about 15 nucleotides in length and having a first consensus splice motif;
- ii) a nucleotide sequence of from about 11 nucleotides to about 15 nucleotides in length and comprising a stop codon in each reading frame;
- and
- iii) a nucleotide sequence of from about 5 nucleotides to about 15 nucleotides in length and having a second consensus splice motif.
(canceled)
36-37. (canceled)
Dependencies are inferred from the claim text.